Physician profile
Adeeb Narangoli
NPI 1194458281
$1,613.62
in general payments reported to CMS, 2019-2025
15 companies · $723 in 2025
The $723 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.35 · 2023: $202 · 2024: $672 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,596.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $214.05 | 2024-2025 | |
| Ucb, INC. | $165.44 | 2024-2025 | Briviact, Rystiggo, Fintepla |
| Takeda Pharmaceuticals U.S.A., INC. | $149.27 | 2023-2025 | Hyqvia |
| Amgen INC. | $148.39 | 2025 | Uplizna |
| Astrazeneca Pharmaceuticals LP | $144.97 | 2024-2025 | Wainua, Andexxa |
| Alexion Pharmaceuticals, INC. | $139.99 | 2023-2024 | Ultomiris |
| Tg Therapeutics, INC. | $115.51 | 2023-2025 | |
| Pfizer INC. | $103.28 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $97.67 | 2023-2025 | Epidiolex |
| Genentech USA, INC. | $95.69 | 2023-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Emd Serono, INC. | $79.50 | 2023-2025 | Mavenclad |
| Lilly USA, LLC | $63.78 | 2025 | Kisunla, Amyvid |
| Sk Life Science, INC. | $61.53 | 2025 | |
| Merck Sharp & Dohme LLC | $17.35 | 2022 | |
| Averitas Pharma INC. | $17.20 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeeb Narangoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.